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Available online 20 July 2016Nearly 50% of cancer patients undergo radiotherapy. Late radiotherapy toxicity affects quality-of-life in long-term
cancer survivors and risk of side-effects in a minority limits doses prescribed to the majority of patients. Devel-
opment of a test predicting risk of toxicity could beneﬁt many cancer patients. We aimed to meta-analyze indi-
vidual level data from four genome-wide association studies fromprostate cancer radiotherapy cohorts including
1564men to identify geneticmarkers of toxicity. Prospectively assessed two-year toxicity endpoints (urinary fre-
quency, decreased urine stream, rectal bleeding, overall toxicity) and single nucleotide polymorphism (SNP) as-
sociations were tested using multivariable regression, adjusting for clinical and patient-related risk factors. A
ﬁxed-effects meta-analysis identiﬁed two SNPs: rs17599026 on 5q31.2 with urinary frequency (odds ratio
[OR] 3.12, 95% conﬁdence interval [CI] 2.08–4.69, p-value 4.16 × 10−8) and rs7720298 on 5p15.2with decreased
urine stream (OR 2.71, 95% CI 1.90–3.86, p-value= 3.21 × 10−8). These SNPs lie within genes that are expressed
in tissues adversely affected by pelvic radiotherapy including bladder, kidney, rectum and small intestine. The re-
sults show that heterogeneous radiotherapy cohorts can be combined to identify new moderate-penetranceKeywords:
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identify enough variants for a future test involving polygenic risk proﬁling.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license (http://
creativecommons.org/licenses/by/4.0/).Table 1
Number of individuals in each cohort.
RAPPER RADIOGEN Gene-PARE CCI
Total in cohort 727 741 895 155
Genotyped via genome-wide SNP chip 672 741 381 155
Excluded: N5% SNPs missing 18 1 8 1
Excluded: cryptic relatedness 14 19 16 0
Excluded: excess heterozygosity 19 – – –
Excluded: PCA outlier – 68 – –
Excluded: non-European ancestry
based on PCA w/ HapMap samples
21 1 67 3
Excluded: lacking all 2 yr toxicity or
essential covariate data
73 55 0 1
Number included in analysis of at least
one toxicity endpoint
527 597a 290b 150c
a Additional follow-up of the RADIOGEN cohort increased the numberwith late toxicity
data available from the 417 reported previously (Fachal et al., 2014). Of the 597 partici-
pants in RADIOGEN, one lacked data on rectal toxicity and seven data on rectal volume
and were excluded from the analysis of rectal bleeding. 120 participants had no data on
baseline urinary frequency and 119 were missing data on decreased urine stream and
were excluded from the respective analyses.
b Of the 290 participants in Gene-PARE, 55 were lacking data for rectal volume and
were excluded from analysis of rectal bleeding. 35 participants did not complete the uri-
nary questionnaire and were excluded from analysis of urinary frequency and decreased
urine stream.
c Of the 150 participants in CCI, 15 were lacking data for rectal volume or diabetes and
were excluded from analysis of rectal bleeding.1. Introduction
Radiotherapy is used in the treatment of up to 50% of cancer patients
and around 40% of long-term cancer survivors underwent radiotherapy
at some point in their treatment. For example, approximately half of the
1.1 million men diagnosed with prostate cancer worldwide each year
receive radiotherapy, and the 5-year relative survival rates approach
100% for non-metastatic disease (Howlader et al., 2013). Althoughmod-
ern treatmentsminimize radiation doses to surrounding normal tissues,
some men develop long-term toxicity (Bentzen et al., 2010). The risk of
severe toxicity limits doses,which aim to keep the prevalence below5%.
Mild and moderate effects are common (10–50% of those treated)
(Alemozaffar et al., 2011; Dearnaley et al., 2012; Heemsbergen et al.,
2006; Kneebone et al., 2004; Resnick et al., 2013; Syndikus et al.,
2010), impact negatively on quality-of-life, and are an important factor
when men consider treatment options (Davison et al., 2002).
There is a need for a test that reﬂects a cancer patient's radiosensitiv-
ity and predicts the likelihood of toxicity. Many assays have been ex-
plored but none proved sufﬁciently reliable for clinical application.
Over the past 15 years interest increased in identifying the genetic var-
iants associated with risk of toxicity. The rationale behind the work is
that a future test based on a germline polygenic risk scorewill not suffer
from the poor reproducibility associated with other assays measuring
radiosensitivity (Barnett et al. 2015).
Mutations associated with well-characterized radiosensitivity syn-
dromes such as ataxia telangiectasia (Taylor et al., 1975) are rare and
do not explain the general inter-individual variation in toxicity follow-
ing radiotherapy (Safwat et al., 2002). Rather, it is hypothesized that
common genetic variants, such as single nucleotide polymorphisms
(SNPs) account for most of the heritability of radiosensitivity (West
and Barnett, 2011). Studies have begun to identify common variants as-
sociated with radiotherapy toxicity. Candidate gene studies showed
rs2868371 in HSPB1 (MIM 602195) (Lopez Guerra et al., 2011; Pang et
al., 2013) and rs1800469 in TGFB1 (MIM 190180) (Guerra et al., 2012)
are associated with late effects of lung radiotherapy; and rs1800629 in
TNF (MIM 191160) (Talbot et al., 2012) and rs1139793 in TXNRD2
(MIM606448) (Edvardsen et al., 2013) are risk SNPs for late toxicity fol-
lowing breast radiotherapy. Genome-wide association studies (GWAS)
identiﬁed a locus on chr11q14.3 associated with rectal bleeding
(Kerns et al., 2013b) and a locus on chr2q24.1 within TANC1 (MIM
611397) associated with overall toxicity (Fachal et al., 2014) following
radiotherapy for prostate cancer. Another study showed more associa-
tions at the p-value b 5× 10−7 level than expected by chance, providing
the strongest evidence to date that many common genetic variants are
associated with risk of toxicity (Barnett et al., 2014).
Recently published GWAS have limitations that we aimed to over-
come by using a meta-analysis approach. The published studies used a
multi-stage approach, where a small ﬁrst-stage cohort was analyzed
for a genome-wide panel of SNPs and only the most signiﬁcant SNPs
were genotyped in validation datasets. Thus, true positive SNPs were
likely missed because they were not tested in the full set of individuals.
Here, the Radiogenomics Consortium (West and Rosenstein, 2010) un-
dertook a meta-analysis of four GWAS in order to maximize statistical
power (Cohn and Becker, 2003) to discover additional risk variants. It
is known that risk factors for late toxicity include not only genetics
but also dosimetric parameters, co-morbidities, and patient demo-
graphics (Barnett et al. 2009). The latter factors can vary between co-
horts as can the treatment (e.g. in prostate cancer: external beam or
brachytherapy; type of fractionation – large or small doses per fraction;
variable use of hormone therapy; variable use of surgery) and scalesused to assess toxicity. Therewere concerns, therefore,whether the het-
erogeneity across cohorts might limit our ability to identify variants.
This study is important because our ability to identify enough SNPs
for a risk proﬁle for clinical implementation is dependent on combining
multiple heterogeneous cohorts. The aimwas to show thatmulti-center
radiotherapy cohorts could be harmonized and analyzed to identify risk
SNPs by increasing the number of individuals analyzed in a single stage
(Skol et al., 2006). STROGAR guidelines (Kerns et al., 2014) for reporting
radiogenomic studies, which build on the STREGA and STROBE guide-
lines (Little et al., 2009; von Elm et al., 2007), were followed throughout.
2. Subjects & Methods
2.1. Participants
The four cohorts (RAPPER, RADIOGEN, Gene-PARE, and CCI) com-
prised individuals with adenocarcinoma of the prostate treatedwith ra-
diotherapy with curative intent. Table 1 shows the number of
individuals in each cohort the number with genome-wide SNP data
available, and the ﬁnal number included in the GWAS meta-analysis
after excluding samples for quality control or due to missing data. In-
formed consent was obtained from all study participants and all studies
conform to standards indicated by the Declaration of Helsinki.
RAPPER (UKCRN1471; n = 727) (Burnet et al., 2006) was approved
by the Cambridge South Research Ethics Committee (05/Q0108/365).
Individuals received neoadjuvant androgen suppression and external
beam radiotherapy, (EBRT): 233 from MRC RT01 (ISRCTN47772397)
(Sydes et al., 2004) and 494 from CHHiP (ISRCTN97182923)
(Dearnaley et al., 2012).
RADIOGEN (n=741)was approved by the Galician Ethical Commit-
tee. Individuals received conformal radical or post-prostatectomy EBRT
at the Clinical University Hospital of Santiago de Compostela, Spain
(Fachal et al., 2012), and 511 individuals had hormone therapy.
Gene-PARE (n= 895) (Ho et al., 2006) was approved by the Mount
Sinai Medical Center Institutional Review Board. Individuals had
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York, and 472 received hormone therapy. 125I (160Gy; TG-43) was
used in those undergoing brachytherapy alone and 103Pd (124Gy) in
those also receiving EBRT (Stock et al., 1995; Stone et al., 2003).
The CCI cohort (n= 155) (Kerns et al., 2013b) was approved by the
Health Research Ethics Board of Alberta (Cancer). Individuals were re-
cruited from the Cross Cancer Institute in Edmonton and the Tom
Baker Cancer Centre in Calgary, Alberta, Canada. All 155 individuals
underwent EBRT and 82 received hormonal therapy.
Total biologic effective dose (BED) (Stock et al., 2006)was calculated
for individuals in all four studies to compare radiation exposure across
studies (α/β= 3).
2.2. Assessment of Late Radiotherapy Toxicity
Participants were assessed prospectively for toxicity (see Table S1).
Toxicity was measured 1.5–2.5 years following treatment with the lat-
est value used if more than one assessment was recorded during this
follow-up window. For rectal bleeding in Gene-PARE, a 1–5 year win-
dow was allowed, because the scoring system assigns grades based on
whether rectal bleeding occurs as a single incident or intermittent
symptoms over time. Urinary endpoints were re-graded to harmonize
across the studies (Table S2). As urinary daytime frequency and
nocturia were recorded separately (RAPPER, Gene-PARE) or as a single
endpoint (RADIOGEN, CCI), they were collapsed into a single endpoint
in RAPPER and Gene-PARE by taking the maximum score between the
two.
Changes in scores from baseline were calculated for each endpoint.
Improvement from baseline (i.e. a negative change in score) was
coded as 0. Table S3 lists the two-year prevalence of the toxicity end-
points in the four cohorts, including samples that were not genotyped.
A Standardized Total Average Toxicity (STAT) score was calculated as
described previously (Barnett et al., 2012b) to provide an overall mea-
sure of toxicity. All samples with 2-year toxicity data available and the
endpoints described in Table S1 were used to calculate STAT.
Data simulation determined the most statistically powerful way to
analyze toxicity: ordinal logistic regression of exact change in toxicity
grade from baseline; binary logistic regression with no change in toxic-
ity grade compared with a ≥1 point increase in toxicity grade; or binary
logistic regression with change in toxicity grade ≤1 point compared
with a ≥2 point change. Genotype and toxicity phenotype data for 600
individualswere simulated under twomodels: (1) null (no association),
and (2) alternative model of linear association characterized by a log-
linear per-allele increase in odds of toxicity. Under both types of
model, genotypes were randomly assigned to each subject according
to one of ﬁve minor allele frequencies (MAF): 0.05, 0.15, 0.25, 0.35 or
0.45. To create the null data set, a toxicity grade was also randomly
assigned to each subject. Datasets representing a log-linear association
between genotype and toxicity were created by assigning each subject
a toxicity risk score that was calculated using their genotype and a
pre-speciﬁed effect size (log(odds ratio) = log(1.5)):
Ri ¼ genotypei  βð Þ− 2MAF βð Þ
for subjects i=1…n;
β the pre-speciﬁed effect size;
(2×MAF×β) the population average.
A random risk was also added to each score, representing non-ge-
netic factors that may inﬂuence toxicity, to create a logistic distribution
of toxicity risk. This logistic distributionwas then used to assign a toxic-
ity grade to each subject such that subjects lying at the high end of the
risk distribution had higher toxicity grades than those at the low end
of the distribution. Under both types of model, two phenotype distribu-
tions were simulated to reﬂect the distributions of urinary frequency
and rectal bleeding observed in RAPPER.Each simulation was repeated 100,000 times. Three regression
models were ﬁtted to each set of simulated data, with toxicity grade
as the outcome variable and genotype as the independent variable.
Each model produced a p-value for comparison.
The power of each type ofmodel applied to the log-linear association
data was assessed by tabulating the number of p-values (out of
100,000) achieving statistical signiﬁcance. Applying a simple Bonferroni
correction to the observed p-values to account for 100,000 test repeats,
a test was considered statistically signiﬁcant if p-value b 5 × 10−6. The
model that detected the most signiﬁcant associations was deemed
most powerful. p-Values obtained from analyses of the null data sets
were assessed for type I error.
Results from 100,000 simulations showed that both ordinal logistic
and binary (no versus ≥1 point change) logistic regressionwere equally
powerful statistical approaches (Table S4), and binary logistic regres-
sion (no change in toxicity grade compared with a ≥1 point increase
in toxicity grade)was used for the primary analysis. Nomodel displayed
higher-than-expected type I errors. Data simulation was performed
using R (R Core Development Team, 2014) with the Ordinal package
(Christensen, 2013).
2.3. Genotyping, Quality Control and Imputation
Germline DNA was genotyped using commercial SNP arrays as part
of previously completed GWAS (Barnett et al., 2014; Fachal et al.,
2014; Kerns et al., 2013a; Kerns et al., 2013b; Kerns et al., 2013c). Qual-
ity control ﬁltering removed SNPs that were missing in N2.5% of sam-
ples, had MAF b1% or displayed frequencies deviating from those
expected under Hardy-Weinberg Equilibrium (p-value b 10−6). Sam-
ples with N5% of SNPs missing, showing cryptic relatedness, showing
excess heterozygosity or being principle component analysis (PCA) out-
liers were removed (Table 1). After ﬁltering, the four datasets had
genotyping rates N99%. To minimize potential confounding by popula-
tion structure, individuals with non-European ancestry (Table 1) were
excluded using PCA performed with samples of known ancestry from
the International HapMap Project (International HapMap, 2003).
Imputation using IMPUTE2 software (Howie et al., 2009) with the
1000 Genomes phase I, version 3 (release date 3/16/2012) reference
panel (1092 individuals from all 14 populations) (Genomes Project et
al., 2012) yielded ~38 million SNPs, small insertions and deletions,
and structural variants in each study. These datasets were ﬁltered as
above in addition to removing SNPs with information score, a measure
of imputation certainty, b0.3. The ﬁnal datasets included in the GWAS
meta-analysis were: 6,672,177 SNPs in 527 RAPPER participants;
6,767,156 SNPs in 597 RADIOGEN participants; 6,627,946 SNPs in 290
Gene-PARE participants; and 6,504,337 SNPs in 150 CCI participants.
SNP rs17599026 was directly genotyped in the RADIOGEN and RAP-
PER samples using a TaqMan assay (forward primer sequence
TGCTCATGATGAAGGTATGCTTTCT, reverse primer sequence
ACAAAACTGTATTCCCAAGACAAAGC and probe sequences
CACCATCCTAAAGCAGTG plus ACCATCCTAAAACAGTG; Applied
Biosystems, Thermo Fisher Scientiﬁc) according to the manufacturer's
standard protocol (PCR annealing and extension performed at 60 °C
for 1 min × 40 cycles). It was not possible to design a TaqMan assay
with high speciﬁcity for rs7720298 as it is immediately adjacent to an-
other SNP (rs7720176).
2.4. Statistical Analysis
Individual GWAS were analyzed using binary logistic (individual
toxicity endpoints) or linear (STAT) regression, adjusting for non-genet-
ic risk factors identiﬁed by QUANTEC (Michalski et al., 2010;
Viswanathan et al., 2010). These were: age at treatment, diabetes, rectal
volume and BED in analysis of rectal bleeding; age at treatment, trans-
urethral resection of the prostate (TURP) prior to radiotherapy, baseline
symptom grade and BED in analysis of urinary endpoints; and all factors
Table 3
Prevalence of radiotherapy toxicity endpoints.
Change in toxicity grade from baselinea
0 1 2 3
Rectal bleeding
RAPPER 446 (85%) 64 (12%) 16 (3%) 1 (b0%)
RADIOGEN 516 (88%) 52 (9%) 16 (3%) 5 (1%)
Gene-PARE 208 (72%) 25 (9%) 49 (17%) 8 (3%)
CCI 110 (73%) 29 (19%) 6 (4%) 6 (4%)
Urinary frequency
RAPPER 482 (91%) 42 (8%) 3 (1%) 0
RADIOGEN 423 (89%) 46 (10%) 7 (2%) 1(b1%)
Gene-PARE 173 (68%) 52 (20%) 25 (10%) 5 (2%)
CCI 120 (80%) 24 (16%) 7 (5%) 0
Decreased urine stream
RAPPER 483 (94%) 18 (4%) 9 (2%) 2 (b1%)
RADIOGEN 472 (99%) 2 (b1%) 3 (1%) 1 (b1%)
Gene-PARE 189 (74%) 34 (13%) 24 (9%) 8 (3%)
CCI NA NA NA NA
a For the Gene-PARE, CCI and RADIOGEN studies, the post-treatment rectal bleeding
grade already accounts for baseline symptoms. For the CCI study, the post-treatment uri-
nary frequency grade already accounts for baseline symptoms.
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PARE and CCI analyses because baseline symptoms were assessed
prior to completion of hormone therapy. Multivariable regression was
performed using SNPTEST software (Marchini et al., 2007) with the
frequentist test and expected method. The expected method uses the
genotype dosages produced from imputation,which account for the un-
certainty in using imputed genotypes rather than experimentally deter-
mined genotypes. Thus, inaccuracy related to using imputed data was
accounted for in the statistical analysis. An additive genetic inheritance
model was assumed in all analyses.
A ﬁxed-effects meta-analysis with inverse variance weighting was
performed using the regression beta coefﬁcients and standard errors pro-
duced by SNPTEST. Studies have shown ﬁxed-effects to be more statisti-
cally powerful compared with random-effects when the primary
purpose is SNP discovery rather than reﬁnement of the effects size esti-
mate (Evangelou and Ioannidis, 2013). A chi-squared test of heterogeneity
was performed for each SNP. SNPs considered signiﬁcant had a meta-p-
value ≤ 5 × 10−8 and agreement in effect direction across all cohorts. Sig-
niﬁcant SNPswere re-analyzed using an ordinal logistic regressionmodel.
Regions of linkage disequilibrium were deﬁned based on r2 ≥ 0.5 in
SNPs from the 1000Genomes Europeanpopulationwith themeta-anal-
ysis top hits using Haploview software (Barrett et al., 2005). The most
recent release of the 1000 Genomes data (version 5, release date 5/2/
2013) was used to estimate linkage disequilibrium.
2.5. Power Calculations
Power calculations were performed using the web-based Genetic
Power Calculator (Purcell et al., 2003) assuming a sample size of 1564
individuals, a phenotype prevalence of 20%, and type I error of 5 × 10−8.
3. Results
Table 2 summarizes the cohort characteristics and Table 3 the toxic-
ity prevalences of the 1564 men treated for prostate cancer who were
included in the analysis. Two years following radiotherapy 17.8% (277
of 1557) of individuals experienced rectal bleeding, 15.0% (212 ofTable 2
Individual study patient characteristics.
RAPPER, N
= 527
RADIOGEN, N
= 597
Gene-PARE, N
= 290
CCI, N =
151
Age, mean (sda) 67 (5.7) 71 (5.8) 64 (7.5) 67 (7.2)
TURPb, n (%) 56 (11%) 45 (8%) 6 (2%) 6 (4%)
Diabetes, n (%) 39 (7%) 144 (24%) 16 (6%) 24 (16%)
Gleason score, n (%)
≤6 261 (50%) 366 (61%) 193 (67%) 30 (20%)
7 231 (44%) 164 (28%) 69 (24%) 97 (64%)
≥8 25 (5%) 60 (10%) 28 (10%) 21 (14%)
missing 10 (2%) 7 (1%) 0 3 (2.0%)
Stage, n (%)
T1 187 (35%) 214 (35.8%) 150 (52%) 38 (25%)
T2 267 (51%) 323 (54.1%) 128 (44%) 89 (59%)
T3 61 (10%) 44 (7.4%) 12 (4%) 16 (11%)
T4 0 0 0 1 (1%)
missing 12 (2%) 17 (2.8%) 0 7 (5%)
Pre-treatment PSAc,
mean (sd)
13.2 (7.5) 16 (20.5) 9.4 (19.4) 15.5
(13.4)
Hormone therapy, n
(%)
527 (100%) 415 (69.5) 147 (51%) 74 (49%)
BEDd, mean (sd) 120.5 (6.2) 120.5 (5.8) 191.9 (22.4) 125.5
(6.2)
Rectum Volume (cm3),
mean (sd)
NAe 56.9 (29.9) 33.9 (13.9) 76.3
(27.7)
a sd, standard deviation.
b TURP, transurethral resection of the prostate.
c PSA, prostate speciﬁc antigen.
d BED, biologically effective dose.
e NA, not available.1410) an increase in urinary frequency, and 8.1% (101 of 1245) a de-
crease in urine stream. The meta-analysis had ≥99% power to detect
SNPs with MAF ≥10% and per-allele effect size ≥2 assuming a ge-
nome-wide signiﬁcance threshold of 5 × 10−8 (Table 4).
Meta-analysis Q-Q plots (Fig. S1) show no genomic inﬂation, sug-
gesting that population structure was adequately controlled using prin-
cipal components analysis to exclude outliers with non-European
ancestry. Themost statistically signiﬁcant SNPs associatedwith late tox-
icity are listed in Tables 5–8, which show several SNPs had meta-p-
values reaching or approaching signiﬁcance (p-value ≤ 5 × 10−6) with
concordant effect direction across the individual studies. Three SNPs
reached genome-wide signiﬁcance: rs17599026 on 5q31.2with urinary
frequency (3.12, 95% CI 2.08–4.69, p-value 4.16 × 10−8); rs7720298 on
5p15.2 with decreased urine stream (OR 2.71, 95% CI 1.90–3.86, p-
value = 3.21 × 10−8); and rs11230328 on 11q12.2 with STAT score
(Beta 0.31, 95% CI 0.21–0.41, p-value = 6.27 × 10−10). rs17599026
was directly genotyped in the GenePARE and CCI studies and imputed
in the RADIOGEN (information score= 0.90) and RAPPER (information
score = 0.87) studies. rs7720298 was imputed in all four studies
(RADIOGEN information score = 0.91, RAPPER information score =
0.93, GenePARE information score = 0.94, and CCI information
score = 0.95) and rs11230328 was imputed in all four studies
(RADIOGEN information score = 0.68, RAPPER information score =
0.61, GenePARE information score = 0.88, and CCI information
score = 0.97). To provide a more interpretable effect size for
rs11230328, STAT score was dichotomized at the mean and analyzed
using logistic regression, which resulted in an OR of 1.59 (95% CI 1.25–
2.02). Therewere nogenome-wide signiﬁcant SNPs associatedwith rec-
tal bleeding, and though several approached signiﬁcance, these require
investigation in future larger studies. Fig. 1 shows forest plots for the
SNPs that reached the genome-wide signiﬁcance threshold.Table 4
Power to detect signiﬁcant associations among 1564 radiotherapy patientsa.
Minor allele frequency
0.05 0.10 0.15 0.25 0.35 0.50
Per-allele odds ratio 1.15 0 0 0 0 0 0
1.25 0 0 0 1% 1% 1%
1.5 1% 7% 21% 47% 59% 56%
2.0 64% 99% 100% 100% 100% 100%
a Assuming a type I error rate of 5 × 10−8 and a disease prevalence of 20%, which was
the approximate average prevalence of the toxicities included in the study.
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154 S.L. Kerns et al. / EBioMedicine 10 (2016) 150–163In order to conﬁrm the quality of the imputation, rs17599026was ge-
notyped directly in the RADIOGEN and RAPPER samples. Genotypingwas
successful in 645 of 654RADIOGEN samples (correlation between the im-
puted and genotyped data of 0.88) and 595 of 600 RAPPER samples (cor-
relation between the imputed and genotyped data of 0.85). These results
conﬁrmed that the genotypes are in strong agreement with the imputed
data. When the direct genotype data was used in analysis, rs17599026
showed an association signal consistentwith that seen using the imputed
data, though the p-value fell short of the strict threshold for genome-
wide signiﬁcance (OR 2.48, 95% CI 1.68–3.63, p-value = 3.66 × 10−6).
Associations between the top SNPs (meta-analysis p-value ≤5×10−6)
and toxicity severityweremodeledusing ordinal logistic regression (Table
9). For all SNPs, the p-value from ordinal logistic regression was similar to
that frombinary logistic regression. For several SNPs the association signal
improved slightly with the ordinal logistic model: rs12497518,
rs141044160, rs6999859, and rs4804134 associated with rectal bleeding;
rs17599026, rs7366282, rs4534636, rs10101158, rs10209697, rs6003982,
and rs7356945 associated with urinary frequency; rs7720298, rs673783,
rs62091368, and rs144596911 associated with decreased urine stream.
Regions of linkage disequilibrium (LD) were deﬁned for the three
loci tagged by SNPs reaching genome-wide signiﬁcance. rs17599026,
associated with urinary frequency, tags a 106 kb region of LD (base po-
sition 137,657,783–137,763,798; Fig. 2A) containing part of KDM3B (in-
cluding the promoter region through exon 20), the upstream FAM53C,
and part of the upstream CDC25C (the promoter region through exon
6). rs7720298, associated with decreased urine stream, tags a 39 kb re-
gion of LD (base position 13,858,328–13,897,362; Fig. 2B) that contains
exons 16 through 30 of DNAH5. rs11230328 was not in strong linkage
disequilibrium with any other common SNPs found in the more recent
release of the 1000 Genomes population data, and this locusmay repre-
sent a spurious association. rs11230328 lies within a LINE element, and
may be difﬁcult tomap in the genomedue to its locationwithin a region
of high homology. Imputation coverage (i.e. the number of SNPs suc-
cessfully imputed in the study datasets out of common SNPs
(MAF ≥ 0.05) within the 1000 Genomes European population) was
high within the regions tagged (correlation r2 ≥ 0.5) by rs17599026
(173/183, 94.5%) and rs7720298 (130/136, 95.6%).
SNPs rs17599026 and rs7720298 are located in non-coding regions,
as is common in GWAS, and the LD blocks tagged by these SNPs cover
coding and non-coding regions. rs17599026, associated with urinary
frequency, lies in an intronic region 23 bp downstream of exon 20 of
KDM3B (MIM 609373; NM_016604.3:c4753+23CNT) encoding the ly-
sine-speciﬁc demethylase 3B protein. KDM3B is highly expressed in
bladder tissue from the Human Protein Atlas project (Uhlen et al.,
2015), suggesting that this gene could be involved in normal bladder
function and potentially dysfunction following damage from radiation
exposure. rs17599026 itself does not lie in a site of known transcription
factor binding or chromatinmodiﬁcation from the Encyclopedia of DNA
Elements (ENCODE) catalog (ENCODE Project Consortium, 2012) and
there are no signiﬁcant expression quantitative trail loci (eQTLs) for
this SNP in the Genotype-Tissue Expression (GTEx) project (GTEx
Consortium, 2013). Given that rs17599026 is very close to exon 20, it
could have an effect on splicing. However, no signiﬁcant splicingmotif al-
terationwas detected using Human Splicing Finder (Desmet et al., 2009).
ENCODE data show that the large LD block tagged by this SNP contains
multiple transcription factor binding sites, DNase hypersensitive sites,
histone methylation sites (methylation of lysine 4 at histone 3,
H3K4Me3 and methylation of lysine 4 at histone 1, H3K4Me1), and his-
tone acetylation sites (acetylation of lysine 27 at histone 3, H3K27Ac)
that may affect regulation of the nearby genes. rs7720298,
associated with decreased urine stream, lies in an intronic region
just downstream of exon 30 of DNAH5 (MIM 603335;
NM_001369.2:c.4950+1233GNC) encoding the dynein, axonemal,
heavy chain 5 protein that is part of a microtubule-associatedmotor pro-
tein complex. Rare mutations in DNAH5 can result in development of ab-
normal cilia and ﬂagella in cells that lead to primary ciliary dyskinesia,
Table 6
Urinary frequency multivariable analysis results (p b 5 × 10−6).
rsID Chr Minor allele MAFa RAPPER, N = 527 RADIOGEN, N = 477 Gene-PARE, N = 255 CCI, N = 150 Meta-analysis, N = 1409
ORb
(95% CIc)
p-Value OR
(95% CI)
p-Value OR
(95% CI)
p-Value OR
(95% CI)
p-Value OR
(95% CI)
p-Value phetd
rs17599026 5q31.2 T 0.08 2.57 (1.28,5.16) 0.012 3.19 (1.57,6.46) 2.36 × 10−3 8.16 (3.04,21.9) 5.88 × 10−6 1.63
(0.59,4.54)
0.358 3.12 (2.08,4.69) 4.16 × 10−8 0.139
rs11574532 12q13.13 T 0.07 1.70 (0.70,4.33) 0.282 3.69 (1.78,7.68) 8.29 × 10−4 3.57 (1.53,8.35) 3.03 × 10−3 5.76 (1.66,19.99) 5.50 × 10−3 3.25 (2.08,5.07) 2.11 × 10−7 0.420
rs342442 4q22.1 T 0.38 0.39 (0.22,0.68) 3.50 × 10−4 0.56 (0.36,0.89) 0.011 0.51 (0.32,0.8) 2.88 × 10−3 0.62
(0.31,1.25)
0.174 0.51 (0.39,0.66) 3.86 × 10−7 0.700
rs4534636 12p13.31 A 0.20 1.27 (0.71,2.27) 0.429 2.48 (1.54,3.99) 2.35 × 10−4 2.06 (1.25,3.41) 4.31 × 10−3 2.03
(0.97,4.25)
0.0461 1.96 (1.49,2.59) 1.67 × 10−6 0.373
rs8098701 18q21.1 T 0.07 2.93 (1.39,6.15) 7.63 × 10−3 2.75 (1.52,4.97) 1.15 × 10−3 1.70 (0.86,3.34) 0.133 2.53
(0.77,8.28)
0.136 2.41 (1.68,3.47) 2.11 × 10−6 0.684
rs7366282e 1q41 C 0.06 2.22 (1.02,4.82) 0.056 4.11 (1.82,9.3) 1.27 × 10−3 3.86 (1.55,9.63) 3.03 × 10−3 NAf NA 3.20 (1.98,5.16) 2.03 × 10−6 0.501
rs10209697 2q36.1 A 0.07 4.09 (1.65,10.1) 4.35 × 10−3 4.32 (2.19,8.5) 5.14 × 10−5 1.53 (0.74,3.14) 0.255 1.36
(0.44,4.27)
0.599 2.66 (1.77,3.99) 2.27 × 10−6 0.093
rs4997823 6q14.1 G 0.35 0.40 (0.22,0.74) 1.90 × 10−3 0.37 (0.2,0.67) 5.69 × 10−4 0.68 (0.42,1.11) 0.118 0.44
(0.20,0.99)
0.040 0.49 (0.36,0.66) 2.35 × 10−6 0.372
rs7356945 6p24.1 T 0.33 2.56 (1.58,4.13) 1.10 × 10−4 1.63 (1.08,2.48) 0.022 1.21 (0.8,1.85) 0.368 2.42
(1.25,4.69)
7.32 × 10−3 1.74 (1.38,2.21) 3.71 × 10−6 0.097
rs6003982 22q11.23 G 0.44 0.67 (0.37,1.19) 0.166 0.46 (0.27,0.79) 3.70 × 10−3 0.39 (0.23,0.67) 4.33 × 10−6 0.60
(0.30,1.19)
0.138 0.51 (0.38,0.68) 4.28 × 10−6 0.549
rs10101158 8q24.3 A 0.44 1.63 (0.95,2.81) 0.074 1.56 (0.98,2.48) 0.063 1.99 (1.3,3.06) 1.24 × 10−3 2.17
(1.14,4.11)
0.015 1.80 (1.40,2.31) 4.39 × 10−6 0.792
a MAF, minor allele frequency.
b OR, odds ratio.
c CI, conﬁdence interval.
d phet = p-value from chi-squared test of heterogeneity.
e rs7366282 was not imputed in CCI.
f NA, not available.
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156 S.L. Kerns et al. / EBioMedicine 10 (2016) 150–163which is a disorder characterized in part by chronic respiratory tract in-
fections (Escudier et al., 2009). In addition to playing an important role
in the lung, DNAH5 is expressed in both kidney and bladder tissue, sug-
gesting a biologic role in normal function of the urinary tract (Uhlen et
al., 2015). This SNP does not lie in a site of known transcription factor
binding or chromatin modiﬁcation from the ENCODE catalog nor is it an
eQTL based on data from GTEx, but the region of LD tagged by
rs7720298 contains several transcription factor binding sites and sites
of DNase hypersensitivity measured in ENCODE cell lines, suggesting
that it may tag a site of transcriptional regulation.
4. Discussion & Conclusions
Thismeta-analysis aimed to identify SNPs associatedwith late radio-
therapy toxicity in a single tumor site. By having a total sample size in a
single stage analysis of N1500menwith prostate cancer (versus ~600 in
published studies), the study identiﬁed two risk loci. This study had
≥99% power to identify common SNPs (MAFs ≥10%) that confer a rela-
tively large increased risk for developing late toxicity (OR ≥2.0). Identi-
ﬁcation of multiple loci in this single-stage meta-analysis versus single
loci in published GWAS that used a staged approach is consistent with
the increased power. The meta-analysis showed that heterogeneity in
radiotherapy datasets is not a barrier for future multi-cohort
radiogenomic studies. The absence of signiﬁcant SNPs associated with
rectal bleeding is consistent with the relatively limited statistical
power. Most common variants identiﬁed via GWAS have more modest
effects (ORs 1.15 to 1.5) than this study was powered to detect. Our
group previously reported an excess of associations at the
p b 5 × 10−7 level for rectal bleeding showing many SNPs should be
identiﬁed as sample sizes increase (Barnett et al., 2014). In addition,
our current approach of dichotomizing toxicity at grade 0 versus grade
1 or worse and considering two years of follow-up may not be optimal
for rectal bleeding, which could be explored as our radiogenomic co-
horts increase.
The signiﬁcant SNPs lie in non-coding regions, as is common in
GWAS where ~64% of identiﬁed SNPs lie in enhancer regions (Hnisz et
al., 2013). Gene enhancer elements are noncoding segments of DNA in-
volved in regulating transcriptional programs (Corradin and Scacheri,
2014). Their location is predicted by DNase I hypersensitive regions of
open chromatin ﬂanked by sties of histone methylation. These en-
hancers can be active (associated with the acylation of lysine 27 of his-
tone 3 [H3K27Ac]) or repressed (correlated with histone marks
H3K27Me3 and H3K9Me3). Although premature to speculate on the
functional consequences of these SNPs, they lie in intronic regions of
genes that are expressed in tissues exposed to radiation during treat-
ment of prostate cancer and are involved in the symptoms experienced
by men having radiotherapy for this malignancy. Fine mapping studies
and functional characterization of causal variants contained within
these loci should expand our understanding of the biology underlying
the pathogenesis of radiotherapy toxicity.
rs17599026 was genotyped to check the quality of the imputed data
from RADIOGEN and RAPPER. Direct genotyping conﬁrmed the high
quality of the imputation, but we were unable to genotype directly the
other two SNPs for which imputed data were used for all four cohorts.
rs7720298 had high imputation information scores (N0.95) in all three
studies of urinary decreased stream, lending conﬁdence to this associa-
tion. However, rs11230328 had a lower imputation quality (b0.70) in
two of the four studies of overall toxicity, and it is not present in the lat-
est 1000 Genomes Project release (v5a; 05/02/2013). Thus, rs11230328
may represent a spurious association.
None of the previously studied candidate gene SNPs for radiotherapy
toxicitywere among the top loci identiﬁed in thismeta-analysis, consis-
tent with a recent validation study showing no evidence for association
between 92 candidate SNPs and radiotherapy toxicity among ~1600 in-
dividuals treated with radiotherapy for breast or prostate cancer
(Barnett et al., 2012a). No SNP discovered in previous GWAS was
Table 8
Overall toxicity (STAT) multivariable analysis results (p b 5 × 10−6).
rsID Chr Minor allele MAFa RAPPER, N = 527 RADIOGEN, N = 474 Gene-PARE, N = 209 CCI, N = 136 Meta-analysis, N = 1,346
Beta (95% CIb) p-value Beta (95% CI) p-value Beta (95% CI) p-value Beta (95% CI) p-value Beta (95% CI) p-value phetc
rs11230328 11q12.2 G 0.27 0.23 (0.06,0.40) 7.96 × 10−3 0.45 (0.29,0.61) 3.50 × 10−8 0.20 (−0.03,0.43) 0.083 0.22 (−0.09,0.53) 0.170 0.31 (0.21,0.41) 6.27 × 10−10 0.154
rs147596965d 10p14 T 0.07 NAe NA 0.75 (0.47,1.03) 2.73 × 10−7 NA NA 0.44 (−0.04,0.92) 0.072 0.67 (0.43,0.91) 6.19 × 10−8 0.150
rs77530448 2q31.1 G 0.09 0.07 (−0.18,0.33) 0.576 0.51 (0.31,0.71) 4.01 × 10−7 0.41 (0.12,0.70) 5.60 × 10−3 0.29 (−0.13,0.70) 0.179 0.36 (0.23,0.49) 7.36 × 10−8 0.060
rs4906759f 15q12 T 0.06 0.34 (−0.02,0.71) 0.063 0.86 (0.54,1.18) 2.28 × 10−7 0.32 (−0.08,0.72) 0.110 NA NA 0.55 (0.34,0.75) 1.55 × 10−7 0.047
rs71610881g 4p15.2 A 0.06 0.70 (0.42,0.97) 1.30 × 10−6 NA NA NA NA 0.36 (−0.06,0.79) 0.098 0.60 (0.36,0.83) 5.41 × 10−7 0.198
rs141799618h 19q13.2 G 0.06 0.33 (0.02,0.65) 0.039 0.50 (0.26,0.74) 5.17 × 10−5 NA NA 0.45 (−0.04,0.94) 0.072 0.44 (0.26,0.62) 1.22 × 10−6 0.698
rs2842169 10q26.2 C 0.10 0.33 (0.12,0.53) 1.73 × 10−3 0.24 (0.07,0.41) 7.54 × 10−3 0.28 (−0.02,0.58) 0.067 0.39 (−0.02,0.81) 0.065 0.28 (0.17,0.40) 1.45 × 10−6 0.863
rs11219068 11q24.1 A 0.15 0.38 (0.17,0.59) 3.56 × 10−4 0.18 (−0.01,0.37) 0.062 0.16 (−0.11,0.43) 0.252 0.49 (0.18,0.79) 2.25 × 10−3 0.28 (0.17,0.40) 1.74 × 10−6 0.204
rs8075565 17p13.2 T 0.13 0.37 (0.16,0.59) 6.43 × 10−4 0.33 (0.14,0.52) 5.91 × 10−4 0.23 (−0.03,0.49) 0.080 −0.01 (−0.33,0.30) 0.933 0.28 (0.16,0.39) 2.20 × 10−6 0.217
rs6535028 4q28.3 T 0.10 0.22 (0.02,0.43) 0.031 0.33 (0.14,0.52) 8.62 × 10−4 0.42 (0.11,0.73) 8.13 × 10−3 0.16 (−0.19,0.51) 0.374 0.29 (0.17,0.40) 2.70 × 10−6 0.615
rs4775602 15q21.1 C 0.16 0.12 (−0.04,0.28) 0.135 0.27 (0.12,0.42) 5.54 × 10−4 0.40 (0.17,0.63) 7.39 × 10−4 0.11 (−0.23,0.44) 0.525 0.23 (0.13,0.32) 3.02 × 10−6 0.240
rs60481745 1p13.3 A 0.10 0.20 (−0.07,0.46) 0.149 0.39 (0.14,0.64) 2.69 × 10−3 0.65 (0.22,1.08) 3.11 × 10−3 0.57 (0.08,1.05) 0.022 0.37 (0.22,0.53) 3.53 × 10−6 0.260
rs7829759 8p23.2 A 0.11 0.46 (0.23,0.69) 1.29 × 10−4 0.22 (−0.02,0.46) 0.078 0.33 (0.02,0.64) 0.042 0.26 (−0.20,0.72) 0.264 0.33 (0.19,0.47) 3.84 × 10−6 0.551
rs79604958i 15q24.2 C 0.07 NA NA 0.35 (0.04,0.66) 0.024 0.44 (0.10,0.78) 0.013 0.77 (0.34,1.21) 6.41 × 10−4 0.47 (0.27,0.68) 4.33 × 10−6 0.289
rs10770857 12p13.31 A 0.37 0.18 (0.05,0.31) 6.02 × 10−3 0.14 (0.02,0.26) 0.017 0.15 (−0.03,0.33) 0.097 0.28 (0.05,0.51) 0.018 0.17 (0.10,0.25) 4.98 × 10−6 0.774
rs12591436 15q25.1 G 0.34 0.23 (0.09,0.37) 1.56 × 10−3 0.16 (0.04,0.28) 8.79 × 10−3 0.14 (−0.07,0.35) 0.178 0.20 (−0.05,0.46) 0.124 0.18 (0.10,0.26) 5.66 × 10−6 0.885
a MAF, minor allele frequency.
b CI, conﬁdence interval.
c phet = p-value from chi-squared test of heterogeneity.
d For rs147596965, RAPPER MAF = 0.045, info = 0.619, beta (95%CI) =−0.14 (−0.53, 0.25), p-value = 0.478; Gene-PARE MAF = 0.044, info = 0.662, beta (95% CI) =−0.31 (−0.83, 0.20), p-value = 0.237.
e NA, not available.
f For rs4906759, CCI MAF = 0.040, info = 0.604, beta (95% CI) =−0.71 (−1.37,−0.05), p-value = 0.035.
g For rs71610881, RADIOGEN MAF = 0.040, info = 0.986, beta (95% CI) = 0.04 (−0.24, 0.33), p-value = 0.761; Gene-PARE MAF = 0.022, info = 0.995, beta (95% CI) =−0.07 (−0.77, 0.63), p-value = 0.841.
h For rs141799618, Gene-PARE MAF = 0.037, info = 0.780, beta (95% CI) =−0.27, (−0.89, 0.35), p-value = 0.395.
i For rs79604958, RAPPER MAF = 0.045, info = 0.499, beta (95% CI) = 0.60 (0.20,1.00), p = 0.0036.
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Fig. 1. Forest plots of signiﬁcant SNPs. SNPs with meta-p-value b 5 × 10−8 associated with: (a) urinary frequency (rs17599026); (b) decreased urine stream (rs7720298); and (c) overall
toxicity (rs11230328). p-Values are frommeta-analysis of regression coefﬁcients and standard errors from regression analysis performed in each study. Odds ratios (OR; urinary frequency
and decreased urine stream) or regression beta coefﬁcient (STAT score) are shown for each individual study aswell as themeta-analysis (Summary). The size of the boxmarking each odds
ratio or beta is proportional to the precision of estimate for the given study. Lines on the boxes denote 95% conﬁdence intervals. ‘Toxicity’ and ‘No toxicity’ (rs17599026 and rs7720298)
was deﬁned as ≥1 point increase in toxicity grade versus no change in toxicity grade from pre-radiotherapy scores. Overall toxicity was analyzed as a continuous variable (STAT).
158 S.L. Kerns et al. / EBioMedicine 10 (2016) 150–163identiﬁed in this de novo analysis, likely due to methodological differ-
ences. The published locus on chr2q24.1, identiﬁed in RADIOGEN and
replicated in RAPPER and Gene-PARE (Fachal et al., 2014),was excluded
because the MAFs of the tagging SNPs were b5%, the threshold set in
this meta-analysis to maximize statistical power. Subsequent to the
meta-analysis, we tested SNPs in the chr2q24.1 locus for replication in
CCI (the only cohort not included in the initial publication) using the
methods of the originally published paper. All seven previously report-
ed SNPs showed a consistent direction of association with overall toxic-
ity in CCI, and rs264651 showed a statistically signiﬁcant association
(linear regression beta = 0.66; 95% CI 0.06, 1.27; p-value = 0.03). The
locus was also tested for association with the three individual toxicity
endpoints investigated in this paper, and appeared to be predominantly
associatedwith urinary toxicity (Table S5). SNPs rs7582141, rs6432512,
rs264588, and rs264631were signiﬁcantly associatedwith an increased
risk for decreased urinary stream and increased urinary frequency
(meta-analysis p-values b 0.05, Table S5). The directions of the associa-
tions were consistent across the other three SNPs, with rs264663 and
rs264651 reaching statistical signiﬁcance for urinary frequency. The di-
rection of the association of six of the seven SNPs was consistent for the
rectal bleeding endpoint, but none of the SNPs approached statistical
signiﬁcance, suggesting that the urinary endpoints are predominantlydriving the association of this locus with overall toxicity. This ﬁnding
thus supports the initial report that chr2q24.1 is a risk locus for late ra-
diotherapy toxicity in prostate cancer. rs7120482 on chr11q14.3 was
previously identiﬁed in Gene-PARE and replicated in a combined
dataset that included RADIOGEN and CCI (Kerns et al., 2013b), but the
associationwith rectal bleedingwas restricted to a recessive inheritance
model. In this meta-analysis, dominant and recessive models were not
considered in order to avoid an increased burden of multiple compari-
sons correction. Subsequent to this meta-analysis, we tested
rs7120482 for replication in RAPPER (the only cohort not included in
that initial publication) using the methods of the originally published
paper. The initial association with rectal bleeding was not replicated in
RAPPER (odds ratio = 0.74; 95% CI 0.08, 7.33; p-value = 0.79). This
lack of replication could be due to differences in the radiotherapy regi-
men or scoring of toxicity - the incidence of rectal bleeding was low in
RAPPER (3%) compared with the other studies (10% to 18%). However,
the initial association fell just short of genome-wide signiﬁcance and
might be a false positive result. At this early stage of radiogenomic
GWAS we expect some initial associations to be lost as sample sizes in-
crease and false-positive ﬁndings are reduced, as seen in other GWAS
meta-analyses (Evangelou and Ioannidis, 2013). Finally, Gene-PARE
previously identiﬁed risk SNPs for erectile dysfunction (Kerns et al.,
Table 9
Ordinal logistic regression results showing association between top SNPs and toxicity grade.
Toxicity endpoint SNP RAPPER RADIOGEN Gene-PARE CCI Meta-analysis
ORa
(95% CIb)
p-Value OR
(95% CI)
p-Value OR
(95% CI)
p-Value OR
(95% CI)
p-Value OR
(95% CI)
p-Value phet
Rectal bleeding rs12497518 0.66 (0.45,0.95) 0.023 0.60 (0.41,0.87) 5.41 × 10−3 0.52 (0.33,0.83) 4.37 × 10−3 0.58 (0.34,0.96) 0.033 0.60 (0.48,0.73) 9.80 × 10−7 0.894
rs141044160 2.54 (1.52,4.26) 8.70 × 10−4 NAc NA 2.62 (1.52,4.52) 7.79 × 10−4 NA NA 2.58 (1.77,3.75) 7.47 × 10−7 0.942
rs6999859 1.74 (1.16,2.62) 8.37 × 10−3 2.10 (1.40,3,14) 3.87 × 10−4 1.38 (0.86,2.22) 0.190 1.51 (0.82,2.75) 0.183 1.70 (1.37,2.13) 2.40 × 10−6 0.567
rs4804134 0.64 (0.44,0.91) 0.012 0.47 (0.32,0.70) 1.20 × 10−4 0.68 (0.42,1.10) 0.113 0.69 (0.39,1.22) 0.209 0.60 (0.48,0.74) 3.15 × 10−6 0.572
rs360071 1.69 (1.19,2.38) 2.83 × 10−3 1.74 (1.21,2.49) 2.72 × 10−3 1.43 (0.92,2.22) 0.108 1.40 (0.83,2.38) 0.213 1.60 (1.31,1.95) 4.34 × 10−6 0.851
rs7432328 2.88 (1.67,4.98) 5.29 × 10−4 NA NA NA NA 3.97 (1.38,11.39) 0.012 3.09 (1.90,5.01) 5.29 × 10−6 0.598
Urinary frequency rs17599026 2.56 (1.28,5.12) 0.012 3.77 (1.79,7.64) 6.97 × 10−4 4.07 (1.96,8.64) 1.71 × 10−4 1.84 (0.64,4.93) 0.250 3.09 (2.11,4.53) 8.06 × 10−9 0.542
rs11574532 1.65 (0.65,4.14) 0.308 3.40 (1.64,6.86) 0.002 2.62 (1.23,5.53) 0.013 4.44 (1.41,13.87) 0.012 2.79 (1.84,4.24) 1.41 × 10−6 0.534
rs342442 0.39 (0.22,0.68) 3.57 × 10−4 0.56 (0.35,0.88) 9.88 × 10−3 0.54 (0.35,0.83) 4.48 × 10−3 0.63 (0.31,1.23) 0.183 0.52 (0.40,0.67) 5.57 × 10−7 0.685
rs7366282 2.44 (1.11,5.36) 0.036 3.69 (1.62,8.08) 2.40 × 10−3 3.80 (1.69,8.40) 1.44 × 10−3 NA NA 3.25 (2.05,5.14) 4.60 × 10−7 0.681
rs4534636 1.28 (0.71,2.28) 0.417 2.50 (1.55,4.03) 2.05 × 10−4 2.07 (1.29,3.34) 2.57 × 10−3 2.18 (1.06,4.49) 0.035 2.00 (1.53,2.62) 4.75 × 10−7 0.361
rs8098701 3.01 (1.44,6.31) 6.05 × 10−3 2.59 (1.44,4.54) 1.79 × 103 1.46 (0.75,2.74) 0.252 2.90 (0.87,8.97) 0.080 2.28 (1.60,3.24) 4.40 × 10−6 0.426
rs10101158 1.62 (0.94,2.78) 0.077 1.55 (0.98,2.46) 0.064 1.96 (1.31,2.94) 9.06 × 10−4 2.06 (1.12,3.93) 0.020 1.78 (1.39,2.27) 3.67 × 10−6 0.830
rs10209697 3.88 (1.58,9.53) 5.55 × 10−3 3.86 (1.98,7.40) 1.25 × 10−4 1.75 (0.86,3.45) 0.119 1.38 (0.41,4.04) 0.584 2.63 (1.78,3.90) 1.38 × 10−6 0.196
rs6003982 0.65 (0.37,1.17) 0.145 0.47 (0.27,0.80) 4.98 × 103 0.39 (0.23,0.65) 2.48 × 10−4 0.61 (0.30,1.18) 0.144 0.50 (0.38,0.67) 2.74 × 10−6 0.557
rs4997823 0.40 (0.22,0.74) 1.89 × 10−3 0.35 (0.19,0.64) 4.02 × 10−4 0.72 (0.44,1.15) 0.170 0.46 (0.20,0.98) 0.044 0.50 (0.37,0.67) 3.74 × 10−6 0.279
rs7356945 2.52 (1.57,4.04) 1.21 × 10−4 1.60 (1.06,2.43) 0.026 1.26 (0.84,1.89) 0.258 2.37 (1.25,4.63) 8.03 × 10−3 1.74 (1.38,2.19) 2.77 × 10−6 0.122
Decreased stream rs7720298 2.20 (1.25,3.88) 7.45 × 10−3 3.38 (1.00,11.37) 0.058d 3.10 (1.96,4.90) 9.29 × 10−7 NA NA 2.75 (1.96,3.88) 6.52 × 10−9 0.618
rs17362923 3.58 (1.97,6.51) 3.28 × 10−5 NA NA 1.96 (1.20,3.20) 7.75 × 10−3 NA NA 2.50 (1.71,3.65) 2.15 × 10−6 0.126
rs76273496 3.96 (1.83,8.59) 1.31 × 10−3 3.25 (0.65,16.14) 0.191d 2.94 (1.37,6.32) 7.72 × 10−3 NA NA 3.39 (2.02,5.68) 3.45 × 10−6 0.865
rs2203205 1.71 (1.16,2.54) 8.72 × 10−3 2.28 (0.94,5.53) 0.063d 1.63 (1.22,2.19) 1.13 × 10−3 NA NA 1.69 (1.35,2.13) 5.35 × 10−6 0.785
rs141342719 5.11 (2.33,11.21) 7.29 × 10−5 1.32 (0.22,7.88) 0.762d 2.58 (1.22,5.45) 0.015 NA NA 3.28 (1.96,5.52) 6.96 × 10−6 0.270
rs673783 2.83 (1.50,5.34) 1.26 × 10−3 2.14 (0.66,6.93) 0.210d 2.32 (1.38,3.89) 1.52 × 10−3 NA NA 2.47 (1.69,3.61) 3.36 × 10−6 0.865
rs62091368 5.93 (2.14,16.41) 1.62 × 10−3 6.85 (1.70,27.60) 0.016d 2.81 (1.17,6.73) 0.024 NA NA 4.29 (2.36,7.80) 1.89 × 10−6 0.422
rs144596911 4.41 (2.10,9.24) 2.24 × 10−4 1.07 (0.10,12.00) 0.954d 3.44 (1.56,7.59) 2.60 × 10−3 NA NA 3.69 (2.18,6.25) 1.20 × 10−6 0.534
a OR, odds ratio.
b CI, conﬁdence interval.
c NA, not available.
d Adjusted for age and biologically effective dose (BED).
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Fig. 2.Regional plots for two loci. Loci taggedby rs17599026 (a) and rs7720298 (b)with points representing the tag SNP reported in this paper shown inpurple circles. Points representing
nearby SNPs are color coded according to linkage disequilibrium r2 value as indicated in the legends. The recombination rate is estimated from samples from the International HapMap
project.
160 S.L. Kerns et al. / EBioMedicine 10 (2016) 150–1632010; Kerns et al., 2013a), but this endpoint was not assessed in the
other studies in the meta-analysis. Thus, previously identiﬁed SNPs re-
main important, and the meta-analysis reports additional loci.
This study has several strengths. First, toxicitywas assessed prospec-
tively in all four studies, which minimizes recall bias. Second, baseline
information ensures any SNP-toxicity associations identiﬁed occur be-
cause of the radiotherapy rather than any pre-existing (possibly
tumor-related) symptoms. Third, a multivariable approach accounted
for relevant treatment and clinical variables. Radiogenomics involves
phenotypes that occur in response to an environmental exposure (i.e.
therapeutic radiation) that is measurable and can be adjusted for.
Fourth, reliable and current imputation methods were used to obtain
comparable and dense SNP maps across the four studies, allowing
meta-analysis of studies involving different SNP genotyping platforms.Without imputation, only 15,144 SNPs were common to all four
datasets, reducing the likelihood of identifying SNPs associated with
late radiotherapy toxicity.
This study has limitations. First, the four studieswere designed inde-
pendently and involved different methods for recording toxicity. End-
points needed harmonizing and the approach might be sub-optimal,
but serves as a useful guide for future radiogenomics studies involving
multiple cohorts. Although endpoints were dichotomized to minimize
differences in toxicity grades across the cohorts, the simulation experi-
ment showed minimal loss of statistical power. Second, there was the
heterogeneity in radiotherapy protocols. For example, Gene-PARE in-
cluded individuals who received brachytherapy with EBRT, which in-
creases urinary toxicity (Sanda et al., 2008). Similarly, the proportion
of individuals who received androgen deprivation differed across the
161S.L. Kerns et al. / EBioMedicine 10 (2016) 150–163studies. This heterogeneity was adjusted for using multivariable analy-
sis and by a meta-analysis approach. Importantly, none of the top
SNPs showed evidence of heterogeneity in effect size across studies
(Tables 5–8). The ﬁrst SNPs identiﬁed are those that rise above such
noise in the data, and the signiﬁcance of our work is that we can ﬁnd
variants despite imperfect datasets. We attempted to control for differ-
ences in radiation dose by adjusting for total biologically effective dose
in each GWAS. However, this is a surrogate for the doses received by
speciﬁc normal tissues. Future cohorts with detailed dosimetry data to
the different organs at risk will improve on our ability to identify
SNPs. The heterogeneity in cohorts should be embraced, as any predic-
tive test must use SNPs that are associated with toxicity across treat-
ment centers and protocols. Last, in order to minimize confounding by
population structure, the present analysis was restricted to individuals
of European ancestry. It will be important for future studies to focus
on other ancestral groups, both for replication of the loci identiﬁed
here and for discovery of additional loci.
While this studywas successful in identifying radiosensitivity SNPs via
a meta-analysis of GWAS, it is modestly sized compared with GWAS of
other diseases and traits, and it should be viewed as the starting point
for expanded radiogenomics studies. Given that our study was not
powered to detect SNPs with odds ratio b 2, many true positive SNPs
will have beenmissed. Also, though the SNPs identiﬁed here reach statis-
tical signiﬁcance and showconsistency acrossmultiple independent stud-
ies, there is still a possibility that theywill fail to replicate in other cohorts.
This is a challenge in GWAS (McCarthy et al., 2008), but meta-analysis
and replication studies have proved successful in validating hundreds of
risk SNPs for a wide variety of diseases and phenotypes. Future large
GWAS meta-analyses will identify additional SNPs, and this work is un-
derway. The Radiogenomics Consortium is a participant in the OncoArray
Network, which is a large collaborative effort to gain new insight into the
genetic architecture and mechanisms underlying several cancers as well
as outcomes related to the their treatment. Approximately 5000 addition-
al DNA samples from individuals treated with radiotherapy for prostate
cancer are being genotyped using the customized OncoArray, and meta-
analysis of this greatly expanded set of GWAS data using themethods de-
veloped in this paperwill uncover additional risk SNPs, provide a platform
for further validation of the SNPs identiﬁed here, and serve as the basis for
future post-GWAS analyses on these conﬁrmed loci.
The last decade saw a rapid expansion of knowledge of the genetics of
disease susceptibility in thegeneral population.Numerous large collabora-
tive GWAS showed that polygenic risk proﬁles can be built based onmul-
tiple SNPs each conferring small effects but together a signiﬁcant
proportion of susceptibility to common diseases. With the rapid decline
in costs for genetic testing, there is growing acceptance that risk prediction
models incorporating genetic and environmental factorswill be important
in future healthcare provision (Chatterjee et al., 2016). In 2012 therewere
an estimated 32.6 million people alive ﬁve years after being diagnosed
with cancer (http://www.cdc.gov/cancer/international/statistics.htm),
andmanywill be livingwith the consequences of treatment. Research de-
veloping models predicting susceptibility to long-term radiation effects is
important and the ﬁndings reported here shows that heterogeneous ra-
diotherapy cohorts can be combined to identify common genetic variants
associatedwith toxicity. Thework provides a basis for larger collaborative
efforts to identify enough variants for a future test involving polygenic risk
proﬁling.
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